Current oncology (Toronto, Ont.) · 2025
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castonguay Mathias, Roy Jean, Claveau Jean-Sébastien, Lachance Sylvie, Delisle Jean-Sébastien, Kiss Thomas, Cohen Sandra, Fleury Isabelle, Mollica Luigina, Ahmad Imran, Bambace Nadia, Bernard Léa, Roy Denis-Claude, Sauvageau Guy, Veilleux Olivier
Аннотация
BACKGROUND: Allogeneic hematopoietic cell transplant (alloHCT) is a curative option for relapsed/refractory B-cell lymphomas (BCLs), but its role in the evolving field of cellular therapy is increasingly unclear as recent advances in transplant procedures have improved outcomes.
METHODS: This retrospective, single-center study included 55 BCL patients (large B-cell lymphoma-LBCL; indolent BCL; and mantle cell lymphoma-MCL) treated with alloHCT from 2015 to 2023 at Hôpital Maisonneuve-Rosemont. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included NRM and GVHD incidence.
RESULTS: A total of 55 patients were included (25 LBCLs, 16 indolent BCLs, 14 MCLs), and 76% of LBCLs were of indolent origin (Richter transformation, transformed follicular lymphoma). After a median follow-up of 6.1, 5.8 and 2.4 years for LBCLs, indolent BCLs and MCLs, their 5-year PFS and OS were 57.2% (IC 95%: 34.2-74.7) and 62.8% (IC 95%: 37.9-80.0), 81.2% (IC 95%: 52.5-93.5) and 93.8% (IC 95%: 63.2-99.1), and 39.0% (IC 95%: 14.3-63.3) and 68.1% (IC 95%: 35.4-86.8), respectively. The 5-year NRM was 16.9% (IC 95%: 8.2-28.3) with a relapse incidence of 23.4%. Overall/grade 3-4 acute GVHD occurred in 43.6% and 18.1% of patients. At 3 years, overall/moderate or severe chronic GVHD incidence was 49% and 34.5%.
CONCLUSIONS: AlloHCT remains a potentially curative option and should be considered for fit patients with chemosensitive FL or LBCLs of indolent origin and a low comorbidity index.
METHODS: This retrospective, single-center study included 55 BCL patients (large B-cell lymphoma-LBCL; indolent BCL; and mantle cell lymphoma-MCL) treated with alloHCT from 2015 to 2023 at Hôpital Maisonneuve-Rosemont. Primary endpoints were overall survival (OS) and progression-free survival (PFS); secondary endpoints included NRM and GVHD incidence.
RESULTS: A total of 55 patients were included (25 LBCLs, 16 indolent BCLs, 14 MCLs), and 76% of LBCLs were of indolent origin (Richter transformation, transformed follicular lymphoma). After a median follow-up of 6.1, 5.8 and 2.4 years for LBCLs, indolent BCLs and MCLs, their 5-year PFS and OS were 57.2% (IC 95%: 34.2-74.7) and 62.8% (IC 95%: 37.9-80.0), 81.2% (IC 95%: 52.5-93.5) and 93.8% (IC 95%: 63.2-99.1), and 39.0% (IC 95%: 14.3-63.3) and 68.1% (IC 95%: 35.4-86.8), respectively. The 5-year NRM was 16.9% (IC 95%: 8.2-28.3) with a relapse incidence of 23.4%. Overall/grade 3-4 acute GVHD occurred in 43.6% and 18.1% of patients. At 3 years, overall/moderate or severe chronic GVHD incidence was 49% and 34.5%.
CONCLUSIONS: AlloHCT remains a potentially curative option and should be considered for fit patients with chemosensitive FL or LBCLs of indolent origin and a low comorbidity index.